Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
Metrics to compare | TPST | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTPSTPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.7x | −3.5x | −0.5x | |
PEG Ratio | −0.03 | 0.01 | 0.00 | |
Price/Book | 2.7x | 2.9x | 2.6x | |
Price / LTM Sales | - | 10.2x | 3.3x | |
Upside (Analyst Target) | 20.6% | 175.5% | 42.8% | |
Fair Value Upside | Unlock | 0.1% | 6.5% | Unlock |